Afimetoran not checked
Bristol Myers Squibb · BMS-986256 · BLN-256
FollowEvery change as it happens, and a Monday email
Trials
2 active
9 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus, Systemic Lupus Erythematosus
- Main trialPhase 2/3
- “This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or without systemic lupus, whose disease has not responded to or who cannot tolerate antimalarial therapy. Participants are assigned by chance to receive afimetoran or a matching placebo capsule once daily for 24 weeks, in addition to their existing standard lupus care. Neither participants nor study staff know which treatment is given. The study is run in two stages under a…”In the company’s words, NCT07881120 on ClinicalTrials.gov
- Other names
- BMS-986256 · BLN-256
Other drugs for Cutaneous Lupus Erythematosus (CLE)
- EnpatoranEMD Serono Research & Development Institute, Inc. · Phase 3
- LitifilimabBiogen · Phase 3
- AnifrolumabAstraZeneca · Phase 3
- VENT-03Ventus Therapeutics U.S., Inc. · Phase 2
- ICP-488Beijing InnoCare Pharma Tech Co., Ltd. · Phase 2
- DB-2304DualityBio Inc. · Phase 1/2
Coming up1
- Apr 2030Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Apr 2030 | Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus | |
| Phase 2Active, not recruiting | 12 Jun 2026 | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | |
| Phase 1Completed | 21 Feb 2020 | A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants | |
| Phase 1Completed | 21 Mar 2021 | Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants | |
| Phase 1Completed | 30 Mar 2021 | Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants | |
| Phase 1Completed | 24 Sep 2021 | A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants | |
| Phase 1Completed | 21 Apr 2023 | A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus | |
| Phase 1Completed | 29 Sep 2023 | A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants | |
| Phase 1Completed | 11 Apr 2024 | A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026